|
|
|
LifeScienceHistory.com - Check us out on Instagram
Take Your Next Career Step with Lundback
Industry News
-
Gilead announces topline data from phase 3 STELLAR-4 study of selonsertib
Gilead announced that STELLAR-4, a Phase 3, randomized, double-blind, placebo-controlled study evaluating safety and efficacy of selonsertib, an investigational, once-daily, oral inhibitor of ASK1, in patients with compensated cirrhosis due to NASH, did not meet the week 48 primary endpoint.
February 11, 2019
More...
|
|
|
|